![](https://danskbiotek.dk/wp-content/uploads/2018/10/logo-responsive.png)
Y-mAbs Announces Recruitment Status for Pivotal Trials 01 July 2019
NEW YORK, July 01, 2019 Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB)... Read more
NEW YORK, July 01, 2019 Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB)... Read more
NEW YORK, July 01, 2019 Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB)... Read more
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”)... Read more
Today, Symphogen called for an ordinary shareholders meeting to be held on 29 May 2019. At the meeting,... Read more
NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
The Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) joins the Global Biofoundries... Read more
The big Chinese fine chemical company Zhejiang NHU invest €5.5 M in the biotech start-up CysBio to... Read more
COPENHAGEN, Denmark — 12 March 2019: Acesion Pharma (“Acesion” or the Company), a Danish biotech... Read more
Oslo, Norway, 13 February, 2019 Vaccibody AS, a clinical stage immuno-oncology company, announced today... Read more